 GAITHERSBURG, Md., June 16, 2021 GLOBE NEWSWIRE -- Altimmune, Inc. Nasdaq: ALT, a clinical-stage biopharmaceutical company, today announced results from a prespecified 6-week interim analysis of its ongoing 12-week, Phase 1, placebo-controlled, single and multiple ascending dose trial of ALT-801, an investigational GLP-1glucagon dual receptor agonist, in healthy overweight and obese volunteers. The study is currently being conducted in Australia under a clinical trial application. 